Edition:
United Kingdom

Geron Corp (GERN.OQ)

GERN.OQ on NASDAQ Stock Exchange Global Select Market

3.94USD
20 Aug 2018
Change (% chg)

$0.02 (+0.51%)
Prev Close
$3.92
Open
$4.00
Day's High
$4.00
Day's Low
$3.85
Volume
413,753
Avg. Vol
939,286
52-wk High
$6.68
52-wk Low
$1.75

Latest Key Developments (Source: Significant Developments)

Geron Corp Files For Mixed Shelf Offering Of Up To $250 Mln
Thursday, 24 May 2018 

May 24 (Reuters) - Geron Corp ::GERON CORP FILES FOR MIXED SHELF OFFERING OF UP TO $250 MILLION - SEC FILING.  Full Article

Geron Reports Q1 Revenue $318,000
Thursday, 10 May 2018 

May 10 (Reuters) - Geron Corp ::GERON CORPORATION REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.04.Q1 REVENUE $318,000.  Full Article

Geron-Latest Time For Janssen Continuation Decision To Continue Development Of Imetelstat In Any Indication Expected By Q4 2018/Q1 2019
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Geron Corp ::GERON -LATEST TIME FOR JANSSEN CONTINUATION DECISION TO CONTINUE DEVELOPMENT OF IMETELSTAT IN ANY INDICATION EXPECTED BY Q4 2018/Q1 2019 - SEC FILING‍​.  Full Article

Geron says first patient dosed in expanded part 1 of imerge clinical trial in myelodysplastic syndromes
Monday, 20 Nov 2017 

Nov 20 (Reuters) - Geron Corp ::Geron announces first patient dosed in expanded part 1 of imerge clinical trial in myelodysplastic syndromes.  Full Article

Geron Corp Q3 loss per share $0.04
Wednesday, 1 Nov 2017 

Nov 1 (Reuters) - Geron Corp ::Geron Corporation reports third quarter 2017 financial results.Q3 loss per share $0.04.Q3 revenue $163,000.Q3 earnings per share view $-0.05 -- Thomson Reuters I/B/E/S.Q3 revenue view $264,000 -- Thomson Reuters I/B/E/S.  Full Article

Geron announces fast track designation grant for imetelstat
Tuesday, 31 Oct 2017 

Oct 31 (Reuters) - Geron Corp :Geron announces fast track designation granted to imetelstat for lower risk myelodysplastic syndromes.Geron Corp - FDA grants fast track designation for potential treatment of adult patients with transfusion-dependent anemia​.Geron- J‍anssen sponsored application for fast track designation using preliminary data from clinical trial being conducted by Janssen in lower risk MDS​.  Full Article

BRIEF-Geron Corporation Reports Q4 Loss Per Share $0.05

* ORATION REPORTS FOURTH QUARTER AND ANNUAL 2017 FINANCIAL RESULTS AND RECENT EVENTS